药学监护对我国糖尿病治疗干预效果的系统评价

发布时间：2018-06-24 01:25

本文选题：药学监护 + 糖尿病　；参考：《中国医院药学杂志》2015年22期

【摘要】：目的:对我国已发表的关于药学监护与糖尿病文献进行系统评价。方法:系统分析基于相关期刊论文(CNKI),维普和万方3个数据库,以"药学监护"与"糖尿病"及"药学服务"与"糖尿病"为关键词组合,检索1990年1月-2015年5月所有相关文献,根据纳入及排除标准,确定入选文献。进行评价指标和纳入文献质量评价分析。结果:共检索到文献810篇,符合纳入标准的36篇;文献报道集中于医院药学监护和少量社区药学监护;样本数量由13例到432例;年龄跨度范围从13岁至91岁。药学监护干预时间超过6个月的有15篇(占41.6%);绝大部分文献中设计有随机对照试验,但Jadad评分值较低;血糖控制率,用药依从性,不良反应发生率作为主要评价指标,干预组均显著性优于对照组。结论:系统评价研究显示药学监护对糖尿病的治疗干预效果起到了积极作用,但大部分试验设计存在方法学缺陷。因此,我国药学监护对糖尿病干预研究设计应更科学合理才能充分体现药学监护的指导意义。
[Abstract]:Objective: to evaluate the literature on pharmaceutical monitoring and diabetes mellitus published in China. Methods: three databases, CNKI, Weip and Wanfang, were systematically analyzed. The key words of "Pharmacological Monitoring" and "Diabetes" and "Pharmaceutical Care" and "Diabetes" were used as key words. All relevant literatures were searched from January 1990 to May 2015, and the selected documents were determined according to the inclusion and exclusion criteria. Carry on the evaluation index and include the literature quality evaluation analysis. Results: a total of 810 articles were retrieved, 36 of which met the inclusion criteria, the literature reports focused on hospital pharmacy monitoring and a small amount of community pharmaceutical monitoring, the sample size ranged from 13 to 432, and the age ranged from 13 to 91 years old. There were 15 articles (41.6%) with pharmaceutical monitoring intervention for more than 6 months, most of the literature designed randomized controlled trials, but the Jadad score was low, the blood glucose control rate, drug compliance, adverse reaction rate were the main evaluation indexes. The intervention group was significantly better than the control group. Conclusion: systematic evaluation studies show that pharmacological monitoring plays a positive role in the treatment of diabetes mellitus, but most of the experimental designs have methodological defects. Therefore, pharmaceutical monitoring in China should be more scientific and reasonable in the design of diabetes intervention research in order to fully reflect the guiding significance of pharmaceutical monitoring.
【作者单位】：华中科技大学同济医学院附属协和医院药剂科;湖北科技学院;
【分类号】：R95

【参考文献】